Sue
April 16, 2021
InSphero's Scientific Ambassador Sue Grepper PhD highlights how to recapitulate clinically observed increase of Aspartate Transaminase (AST) levels in preclinical in vitro safety studies. If you have experienced a clinical […]
May 1, 2020
An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
September 23, 2019
Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019
InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog. She […]
June 18, 2018
In honor of the inaugural International NASH Day, Insphero explains why we need better preclinical models for non-alcoholic steatohepatitis (NASH) disease drug discovery. Non-alcoholic fatty liver disease (NAFLD) is one of […]